Baxter International Inc.
BAXBaxter International Inc. is a global healthcare company specializing in medical products and services, including dialysis, intravenous solutions, and biopharmaceuticals. Founded in 1931, the company focuses on supporting patient care through innovative therapies and medical devices across hospitals, clinics, and homes worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 1, 2026 | $0.01 | 2026-05-29 | 2026-05-29 |
| April 1, 2026 | $0.01 | 2026-02-27 | 2026-02-27 |
| January 2, 2026 | $0.01 | 2025-11-28 | 2025-11-28 |
| October 1, 2025 | $0.17 | 2025-08-29 | 2025-08-29 |
| July 1, 2025 | $0.17 | 2025-05-30 | 2025-05-30 |
Dividends Summary
- Consistent Payer: Baxter International Inc. has rewarded shareholders with 83 dividend payments over the past 22 years.
- Total Returned Value: Investors who held BAX shares during this period received a total of $23.12 per share in dividend income.
- Latest Payout: The most recent dividend of $0.01/share was paid 17 days ago, on July 1, 2026.
- Yield & Schedule: BAX currently pays dividends quarterly with an annual yield of 0.88%.
- Dividend Growth: Since 2004, the dividend payout has decreased by 98.3%, from $0.58 to $0.01.
Company News
The global human fibrinogen concentrate market, valued at USD 0.95 billion in 2025, is projected to grow at a 11.3% CAGR to reach USD 2.78 billion by 2035. Growth is driven by increasing bleeding disorders, surgical procedures, and demand for effective hemostatic therapies. Lyophilized forms dominate the market, with hospitals being the primary e...
Becton Dickinson (BDX) trades at a 13x forward P/E multiple, representing a significant discount to medtech peers despite strong fundamentals including 60% U.S. infusion pump market share, 90%+ recurring revenue, and record 25% adjusted operating margins. The post-spin-off transition year narrative masks an emerging pure-play MedTech company with...
The global robotic pharmacy prescription market is experiencing significant growth, expanding from USD 214.16 million in 2025 to USD 237.65 million in 2026, with a projected CAGR of 9.18% through 2032, reaching USD 396.21 million. The market is driven by automation adoption for medication safety and efficiency, workforce transformation toward cli...
The Iran-Israel conflict and potential Strait of Hormuz disruption are creating supply chain pressures on medical supplies through petrochemical derivatives. Key inputs like naphtha and methanol used in pharmaceutical packaging and drug synthesis are experiencing price increases. While hospitals haven't yet felt the impact, analysts expect cost p...
Baxter International faces a significant supply shortage of ifosfamide cancer drugs across the European Union due to a technical disruption at a third-party manufacturing facility. The company, the primary EU supplier, has implemented quota-based distribution and advised healthcare providers to prioritize existing patients. Supply constraints are...
